Scarica l'app Stockscreener
80.82
2.12%
1.68
Dopo l'orario di chiusura:
80.99
0.17
+0.21%
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
Ionis to hold third quarter 2023 financial results webcast - GuruFocus
Ionis Pharmaceuticals, Inc. $IONS Shares Sold by Hudson Bay Capital Management LP - MarketBeat
Marex Group plc Buys New Shares in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Hudson Bay Capital Management LP Has $29.63 Million Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Levels Update: Can Ionis Pharmaceuticals Inc stock sustain market leadershipJuly 2025 Review & Real-Time Volume Trigger Notifications - moha.gov.vn
Adage Capital Partners GP L.L.C. Raises Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study - MSN
Ionis Pharmaceuticals Sees Rapid Rise On RNA Drug Progress - Finimize
B of A Securities Maintains Ionis Pharmaceuticals (IONS) Buy Recommendation - Nasdaq
Ionis Pharmaceuticals (IONS) Price Target Raised by B of A Securities | IONS Stock News - GuruFocus
Angioedema Pipeline 2025: FDA Approvals and Clinical Trials - openPR.com
450,254 Shares in Ionis Pharmaceuticals, Inc. $IONS Acquired by Norges Bank - MarketBeat
Polycythemia Vera Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Novartis, Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharm - Barchart.com
Multiple System Atrophy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro - Barchart.com
Can Ionis Pharmaceuticals Stock Hold Up When Markets Turn? - Trefis
Has Ionis Pharmaceuticals Run Too Far After 135% Surge and Bullish DCF Outlook? - Yahoo Finance
Ionis Pharmaceuticals Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
How Twin FDA Breakthrough Therapy Wins Could Impact Ionis Pharmaceuticals (IONS) Investors - Sahm
Kennedy Capital Management LLC Has $5.22 Million Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Hsbc Holdings PLC Purchases 33,461 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Capital Fund Management S.A. Sells 26,795 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NRXP), Akebia Therapeutics (AKBA) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) Director Sells $2,262,960.00 in Stock - MarketBeat
Rx Rundown: Bristol Myers Squibb, Retro Bio, Ionis Pharmaceuticals and more - Medical Marketing and Media
Is Ionis Pharmaceuticals Inc. (ISI) stock suitable for passive index fundsEarnings Growth Summary & Accurate Entry/Exit Alerts - Newser
What Does the Market Think About Ionis Pharmaceuticals Inc? - Benzinga
Is Ionis Pharmaceuticals Inc. (ISI) stock undervalued after correctionJuly 2025 Catalysts & Weekly High Momentum Picks - Newser
Is Ionis Pharmaceuticals Inc. (ISI) stock attractive post correctionFed Meeting & Weekly High Return Stock Forecasts - Newser
How Ionis Pharmaceuticals Inc. (ISI) stock compares with tech leadersMarket Activity Summary & Community Consensus Stock Picks - Newser
Ionis Pharmaceuticals stock hits 52-week high at 82.97 USD By Investing.com - Investing.com South Africa
Ionis Pharmaceuticals stock hits 52-week high at 82.97 USD - Investing.com
Ionis Pharmaceuticals stock maintains Buy rating at TD Cowen on growth outlook - Investing.com Canada
Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows - Sahm
FDA grants breakthrough therapy status to Ionis’ Alexander disease drug By Investing.com - Investing.com Canada
Granite Investment Partners LLC Trims Stock Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Why Ionis Pharmaceuticals Inc. (ISI) stock could break out in 2025July 2025 Pullbacks & Daily Volume Surge Trade Alerts - Newser
American Century Companies Inc. Raises Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
How robust is Ionis Pharmaceuticals Inc. (ISI) stock financial position - Newser
What hedge fund activity signals for Ionis Pharmaceuticals Inc. stock2025 Bull vs Bear & Consistent Income Trade Recommendations - Newser
Ionis gets FDA breakthrough therapy status for zilganersen - MSN
Ionis Pharmaceuticals (NASDAQ:IONS) Hits New 52-Week HighStill a Buy? - MarketBeat
Ionis Pharmaceuticals (IONS) Gains FDA Breakthrough Therapy Desi - GuruFocus
FDA Grants Breakthrough Therapy Status to Ionis Pharmaceuticals' Zilganersen (IONS) - GuruFocus
Ionis Pharmaceuticals' Investigational Alexander Disease Treatment Granted Breakthrough Therapy Designation - marketscreener.com
FDA grants breakthrough therapy status to Ionis’ Alexander disease drug - Investing.com
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD) - Business Wire
How Ionis Pharmaceuticals Inc. (ISI) stock performs during market turbulenceEntry Point & Low Risk Entry Point Tips - Newser
FDA grants breakthrough therapy status to Ionis’ olezarsen for severe HTG - Investing.com Australia
Ionis Pharmaceuticals (IONS): Valuation Perspective Following FDA Breakthrough Therapy Milestone for Olezarsen - Sahm
Ionis Pharmaceuticals (IONS): Valuation Insights Following FDA Breakthrough Therapy Status for Olezarsen - Yahoo Finance
Ionis Pharmaceuticals (IONS) Up 5.4% After EMA Nod and $700M Raise—Has the Bull Case Changed? - Yahoo Finance
Ionis receives U.S. FDA breakthrough therapy designation for olezarsen for severe hypertriglyceridemia - marketscreener.com
Ionis Says Olezarsen Gets FDA Breakthrough Therapy Designation for Severe Hypertriglyceridemia - marketscreener.com
FDA Grants Breakthrough Therapy Designation to Ionis Pharmaceuti - GuruFocus
Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference - The Manila Times
Ionis Pharmaceuticals shares up 3.5% premarket after co receives FDA breakthrough therapy designation for olezarsen for SHTG - marketscreener.com
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG) - Business Wire
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):